Insights From the Comparative Efficacy and Safety of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel in Real-World Relapsed/Refractory Multiple Myeloma: A Retrospective Intention-to-Treat Analysis

EP: 1.Welcome to This OncLive Peer Exchange: Highlighting Key Abstracts From ASH 2024

Now Viewing

EP: 2.Insights From the Comparative Efficacy and Safety of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel in Real-World Relapsed/Refractory Multiple Myeloma: A Retrospective Intention-to-Treat Analysis

EP: 3.Application of Real-World Evidence in Selecting CAR T in R/R MM

EP: 4.Overview of iMMagine-1 Trial: Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of R/R MM

Video content above is prompted by the following:

CAR T-Cell Therapies in R/R Multiple Myeloma: Real-World Insights

Key Findings

• This retrospective intention-to-treat analysis compared the real-world efficacy and safety of 2 CAR T-cell therapies: ciltacabtagene autoleucel (cilta-cel) and idecabtagene vicleucel (ide-cel) in R/R MM.

Comparative Performance

• Evaluated real-world outcomes to bridge the gap between controlled clinical trials and actual patient experiences
• Aimed to understand how these therapies perform in a more diverse, less controlled patient population

Potential Implications

• Provides critical insights into:
• Comparative effectiveness of 2 different CAR T-cell approaches
• Real-world safety profiles
• Practical considerations for treatment selection
• Patient outcomes outside of strict clinical trial protocols

Limitations and Considerations

• Retrospective study design
• Potential selection bias
• Need for further prospective validation

Clinical Relevance

• Helps physicians make more informed treatment decisions
• Offers a more nuanced understanding of CAR T-cell therapy performance in R/R MM